Browsing by Author Joshua, Douglas

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 54  next >
Issue DateTitleAuthor(s)Citation
2015American Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple MyelomaJoshua, Douglas; Bruno, Benedetto; Cook, Gordon; Durie, Brian; et al, Various; Gahrton, Gosta; Garderet, Laurent; Giralt, Sergio; Hari, Parameswaran N.; Krishnan, Amrita; Lokhorst, Henk; McCarthy, Philip L.; Central Clinical School: MedicineAmerican Society of Blood and Marrow Transplant, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.21, 12, 2015,pp 2039-2051
2004B7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Ross; Murray, Allan; Pope, Belinda; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyB7+ T Cells In Myeloma: An Acquired Marker Of Prior Chronic Antigen Presentation., Leukemia & lymphoma, vol.45,(2),2004,pp 363-371
2002The biology and cytogenetics of multiple myelomaGibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Brown, Roderick W.; Campbell, Lynda J.; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThe biology and cytogenetics of multiple myeloma, Reviews in Clinical and Experimental Hematology, vol.6, 3,pp 276-300
2004Bisphosphonate Infusions: Patient Preference, Safety And Clinic Use.Joshua, Douglas; Abren Lourenco, R; Chern, B; Copeman, M; Joseph, David; Lowe, S; Lynch, K; Pittman, K; Richardson, G; Schou, M; Central Clinical School: MedicineBisphosphonate Infusions: Patient Preference, Safety And Clinic Use., Supportive Care in Cancer, vol.12,(6),2004,pp 463-466
2017Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroupJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Hajek, Roman; Ludwig, Heinz; Moreau, Philippe; Niesvizky, R.; Pour, Ludek; Central Clinical School: MedicineCarfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup, Leukemia & Lymphoma, vol.58, 10, 2017,pp 2501-2504
2017Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Hajek, Roman; Ludwig, Heinz; Niesvizky, R.; Oriol, Albert; Orlowski, Robert Z; Central Clinical School: MedicineCarfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial, The Lancet Oncology, vol.18, 10, 2017,pp 1327-1337
2017Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORJoshua, Douglas; Chng, W-J; Dimopoulos, Meletios A; et al, Various; Facon, Thierry; Goldschmidt, Hartmut; Ludwig, Heinz; Moreau, Philippe; Niesvizky, R.; Palumbo, Antonio; Pour, Ludek; Central Clinical School: MedicineCarfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR, Leukemia, vol.31, 6, 2017,pp 1368-1374
2016A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetBradstock, Kenneth; Bryant, Christian; Clark, Georgina; Fromm, Phillip; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Lee, Kenneth; Silveira, Pablo; Brown, Ross D.; Clarke, Candice; Cunningham, Ilona; Gibson, John; Kupresanin, Fiona; Newman, Elizabeth; Suen, Hayley; Western Clinical School: Westmead Institute for Medical Res; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteA CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset, Immunology and Cell Biology, vol.94, 5, 2016,pp 447-457
2016A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetBradstock, Kenneth; Bryant, Christian; Clark, Georgina; Fromm, Phillip; Hart, Derek; Ho, Joy Phoebe; Joshua, Douglas; Lee, Kenneth; Silveira, Pablo; Brown, Ross D.; Clarke, Candice; Cunningham, Ilona; Gibson, John; Kupresanin, Fiona; Newman, Elizabeth; Suen, Hayley; Western Clinical School: Westmead Institute for Medical Res; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteA CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subset, Immunology and Cell Biology, vol.94, 5, 2016,pp 447-457
2012CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosisGibson, John; Hart, Derek; Joshua, Douglas; Brown, Ross; Favaloro, James; Fromm, Phillip D; Joy Ho, P; Karieshma, Kabani; Nassif, Najah T; Suen, Hayley; Woodland, N. B.; Yang, Shihong; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Central Clinical School: MedicineCD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells T cells and are associated with poor prognosis, Blood, vol.120, 10, 2012,pp 2055-2063
2010Characterisation and relevance of CD138-negative plasma cells in plasma cell myelomaJoshua, Douglas; Aklilu, Esther; Brown, R. D.; Ho, P. Joy; Kabani, Karieshma; Reid, S; Woodland, N. B.; Yang, Shihong; Central Clinical School: MedicineCharacterisation and relevance of CD138-negative plasma cells in plasma cell myeloma, International Journal of Laboratory Hematology, vol.32, 6 part 1,pp 190-196
2001Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartmentBasten, Antony; Baxter, Alan; Fazekas De St Groth, Barbara; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Roderick W.; Giesajtis,, G; Raitakari, M.; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Centenary Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyClonal cytotoxic T cells are expanded in myeloma and reside in the CD8+Cd57+CD28- compartment, Blood, vol.98,(9),2001,pp 2817-2827
2010Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapyChen, Yuling; Joshua, Douglas; Li, Jia; Loh, Yen; Sze, Daniel; Yamagishi, Tetsuo; Aklilu, Esther; Brown, Ross D.; Cowley, Mark J.; Ho, P. Joy; Kabani, Karieshma; Kaplan, Warren; Mo, Sulin; Yang, Shihong; Pharmacy; Central Clinical School: Medicine; Chemistry; Pharmacy; Pharmacy; School of Medical Sciences: School of Medical SciencesClonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy, Blood, vol.115, 17,pp 3580-3588
2016CMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responsesBradstock, Kenneth; Bryant, Christian; Clark, Georgina; Fromm, Phillip; Hart, Derek; Ho Lo, Tsun; Horvath, Lisa; Joshua, Douglas; Papadimitrious, Michael Stephen; Silveira, Pablo; Van Kooten Losio, Nicolas; Verma, Nirupama; Anguille, Sebastien; Barnard, Ross; et al, Various; Hsu, Jennifer; Mahler, Stephen; Munster, David; Nagasakid, Tomoko; Prue, R; Turtle, Cameron; Vukovic, Peter; Western Clinical School: Westmead Institute for Medical Res; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Central Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: ANZAC Research InstituteCMRF-56+ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses, OncoImmunology, vol.5, 6, 2016,pp 1-12
2004Either Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β₁ In Patients With Myeloma.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Sze, Daniel; Brown, Ross; Hart, Derek; Murray, Allan; Pope, Belinda; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; PharmacyEither Interleukin-12 Or Interferon-γ Can Correct The Dendritic Cell Defect Induced By Transforming Growth Factor β₁ In Patients With Myeloma., British Journal of Haematology, vol.125,(2),2004,pp 743-748
2004Evolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic.Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineEvolving Transplant Options For Multiple Myeloma: Autologous And Nonmyeloablative Allogenic., Transplantation Proceedings 2005, vol.36,(8),2004,pp 2501-2503
2011Factors influencing the abundance of the side population in a human myeloma cell lineFan, Kei; Joshua, Douglas; Li, Jia; Li, Qian (George); Loh, Yen; Roufogalis, Basil; Smith, Adrian; Sze, Daniel; Brown, Ross D.; Chen, Yuling; Mo, Sui-Lin; Ng, Michelle; Pharmacy; Central Clinical School: Medicine; Chemistry; Pharmacy; Pharmacy; Pharmacy; Medicine; Schl Information TechnologiesFactors influencing the abundance of the side population in a human myeloma cell line, Bone Marrow Research, vol.2011, N/A, 2011,pp 524845-1-524845-8
2011Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in MyelomaJoshua, Douglas; Anderson, Kenneth; Davies, Faith; Laubach, Jacob; Miguel, Jesus; Mitsiades, Constantine; Richardson, P; Central Clinical School: MedicineFuture Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma, Journal of Clinical Oncology, vol.29, 14, 2011,pp 1916-1923
2016High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantationEarl, John; Gurney, Howard; Joshua, Douglas; Kerridge, Ian; McLachlan, Andrew; Shaw, Peter; Trotman, Judith; Kwan, Yiu Lam; Nath, Christa; Nivison-Smith, Ian; Presgrave, Peter; Tiley, Campbell; Zeng, Lihua; Childrens Hospital Westmead: Paediatrics & Child Health; Western Clinical School: Medicine (Westmead); Central Clinical School: Medicine; School of Public Health: Ctr for Values Ethics & Law in Med; Pharmacy; Childrens Hospital Westmead: Paediatrics & Child Health; Concord Clinical School: MedicineHigh melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation, British Journal of Clinical Pharmacology, vol.82, 1, 2016,pp 149-159
2004The Immune System In MyelomaBrown, Richard; Gibson, John; Ho, Phoebe (Joy); Joshua, Douglas; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: Medicine; Central Clinical School: MedicineThe Immune System In Myeloma in Multiple myeloma and related disorders, Hodder Arnold, 2004, pp. 29-46-N/A